CompoundIQ

Disclaimer

CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.

SARMIntermediateHigh Risk

RAD-140

Also known as: Testolone

RAD-140 is a potent non-steroidal SARM developed by Radius Health. It has shown neuroprotective properties in preclinical studies and is currently in early clinical trials for breast cancer.

Evidence48/100 — Emerging

Risk Level

High Risk

Difficulty

Intermediate
CAS Number1182367-47-0
Molecular FormulaC20H16ClN5O2
ClassSARM
CategorySARMs

Mechanism of Action

RAD-140 is a potent and selective androgen receptor agonist in muscle and bone. Preclinical data suggests it crosses the blood-brain barrier and may offer neuroprotective effects. It acts as a competitive antagonist to testosterone in prostate tissue.

Dosing Research

Preclinical studies used 0.01-1 mg/kg in primates. Research community references 10-20 mg/day. Half-life approximately 60 hours. Cycles typically 8 weeks.

Side Effects & Risks

Significant hormonal suppression. Cases of drug-induced liver injury reported in case studies. Potential cardiovascular strain. Limited human safety data — most evidence is preclinical.

Research Studies

Disclaimer

CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.

Send Feedback

Help us improve CompoundIQ